PMID- 38321868
OWN - NLM
STAT- MEDLINE
DCOM- 20240329
LR  - 20240329
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 24
IP  - 3
DP  - 2024 Mar
TI  - Clinical use of biologics for Crohn's disease in adults: lessons learned from 
      real-world studies.
PG  - 171-189
LID - 10.1080/14712598.2024.2316180 [doi]
AB  - INTRODUCTION: The therapeutic armamentarium for managing Crohn's disease (CD) has 
      expanded significantly in recent decades. Several biologics with three different 
      mechanisms of action [anti-tumor necrosis factor (TNF)-alpha, anti-integrin alpha4beta7, and 
      anti-IL 12/23] are currently available to manage CD. AREA COVERED: This narrative 
      review aims to summarize the most significant efficacy and safety data on the use 
      of infliximab (IFX), adalimumab (ADA), vedolizumab (VDZ) and ustekinumab (UST) 
      for the treatment of CD obtained from studies conducted in the real world (RW), 
      compared to the results of randomized clinical trials (RCTs). EXPERT OPINION: RW 
      studies reported that biologic agents included in this analysis have higher 
      remission rates and lower adverse event rates than findings from RCTs for 
      treating patients with CD. All biological agents have proven effective and safe 
      in RW studies, even when using biosimilars or switching to subcutaneous 
      administration of the molecules for which they are available. Finally, anti-TNF-alpha 
      agents, particularly IFX, have a higher rate of adverse events (AEs) than VDZ and 
      UST. Therefore, patients at higher risk of AEs may benefit from other biologics 
      than anti-TNF-alpha. However, further long-term RW studies are needed to confirm 
      these findings.
FAU - Tursi, Antonio
AU  - Tursi A
AUID- ORCID: 0000-0001-5767-5541
AD  - Territorial Gastroenterology Service, ASL BAT, Andria, Italy.
AD  - Department of Medical and Surgical Sciences, Catholic University, School of 
      Medicine, Rome, Italy.
FAU - Mocci, Giammarco
AU  - Mocci G
AD  - Division of Gastroenterology, "Brotzu" Hospital, Cagliari, Italy.
FAU - Del Gaudio, Angelo
AU  - Del Gaudio A
AD  - Division of Internal Medicine and Gastroenterology, Policlinico Universitario "A. 
      Gemelli" IRCCS Foundation, Rome, Italy.
FAU - Papa, Alfredo
AU  - Papa A
AD  - Department of Medical and Surgical Sciences, Catholic University, School of 
      Medicine, Rome, Italy.
AD  - Division of Internal Medicine and Gastroenterology, Policlinico Universitario "A. 
      Gemelli" IRCCS Foundation, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240223
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Biological Products)
RN  - FYS6T7F842 (Adalimumab)
RN  - B72HH48FLU (Infliximab)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - FU77B4U5Z0 (Ustekinumab)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Crohn Disease/drug therapy
MH  - *Biological Products/adverse effects
MH  - Adalimumab/adverse effects
MH  - Infliximab/adverse effects
MH  - Tumor Necrosis Factor-alpha/therapeutic use
MH  - Ustekinumab/adverse effects
MH  - Retrospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Crohn's disease
OT  - anti-TNF-alpha
OT  - efficacy
OT  - safety
OT  - ustekinumab
OT  - vedolizumab
EDAT- 2024/02/07 06:42
MHDA- 2024/03/29 06:45
CRDT- 2024/02/07 02:43
PHST- 2024/03/29 06:45 [medline]
PHST- 2024/02/07 06:42 [pubmed]
PHST- 2024/02/07 02:43 [entrez]
AID - 10.1080/14712598.2024.2316180 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2024 Mar;24(3):171-189. doi: 
      10.1080/14712598.2024.2316180. Epub 2024 Feb 23.